Jacobs Levy Equity Management Inc. Buys Shares of 118,976 Anika Therapeutics, Inc. (NASDAQ:ANIK)

Jacobs Levy Equity Management Inc. bought a new stake in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 118,976 shares of the biotechnology company's stock, valued at approximately $1,958,000. Jacobs Levy Equity Management Inc. owned about 0.81% of Anika Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ANIK. Alta Fundamental Advisers LLC increased its stake in shares of Anika Therapeutics by 136.6% in the fourth quarter. Alta Fundamental Advisers LLC now owns 700,432 shares of the biotechnology company's stock valued at $11,529,000 after buying an additional 404,350 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Anika Therapeutics by 431.9% in the fourth quarter. JPMorgan Chase & Co. now owns 82,491 shares of the biotechnology company's stock valued at $1,358,000 after purchasing an additional 66,982 shares in the last quarter. Capital Management Corp VA lifted its holdings in shares of Anika Therapeutics by 12.1% in the fourth quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company's stock valued at $5,358,000 after purchasing an additional 35,195 shares in the last quarter. Boothbay Fund Management LLC lifted its holdings in shares of Anika Therapeutics by 5.1% in the fourth quarter. Boothbay Fund Management LLC now owns 529,503 shares of the biotechnology company's stock valued at $8,716,000 after purchasing an additional 25,665 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Anika Therapeutics during the fourth quarter worth $352,000. 91.53% of the stock is currently owned by institutional investors.

Anika Therapeutics Stock Up 8.1%

Shares of ANIK stock opened at $12.24 on Friday. The business has a 50-day moving average price of $14.41 and a two-hundred day moving average price of $16.19. Anika Therapeutics, Inc. has a 12-month low of $11.11 and a 12-month high of $29.12. The firm has a market cap of $175.53 million, a P/E ratio of -1.84 and a beta of 0.76.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The firm had revenue of $30.60 million for the quarter, compared to the consensus estimate of $29.00 million. As a group, research analysts expect that Anika Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on ANIK. B. Riley assumed coverage on Anika Therapeutics in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Barrington Research decreased their price objective on Anika Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research note on Monday. Finally, StockNews.com lowered Anika Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.